Management of Vasodilatory Shock in Chronic Liver Disease

Initial Assessment and Hemodynamic Characterization

The American Association for the Study of Liver Diseases recommends performing immediate bedside echocardiography to differentiate between vasodilatory shock, cirrhotic cardiomyopathy, or portopulmonary hypertension with right ventricular dysfunction in patients with chronic liver disease 1, 3
Comprehensive assessment of volume status should be done using physical examination, echocardiographic evaluation of inferior vena cava and cardiac preload, dynamic hemodynamic monitoring, and end-organ perfusion markers in patients with chronic liver disease 1, 3

The American College of Gastroenterology recommends initiating norepinephrine as the first-line vasopressor to maintain adequate organ perfusion pressure, targeting a MAP of 65 mm Hg, in patients with chronic liver disease and vasodilatory shock 1, 2, 4
Vasopressin may be added as a second-line agent when increasing doses of norepinephrine are required, as vasopressin deficiency is documented in cirrhosis 1, 2, 4, 5

The European Association for the Study of the Liver suggests considering empiric hydrocortisone for refractory shock requiring high-dose vasopressors in patients with chronic liver disease, as relative adrenal insufficiency occurs in 49% of patients with cirrhosis and acute decompensation 1, 2, 4, 5, 6
The ADRENAL and APROCCHSS trials documented earlier shock reversal and potential mortality benefit with hydrocortisone in refractory shock, with a recommended treatment duration of 7 days or until ICU discharge 2, 5, 6

The American Association for the Study of Liver Diseases recommends using balanced crystalloids as first-line fluid if any volume resuscitation is needed in patients with chronic liver disease, to limit the risk of hyperchloremic acidosis and subsequent adverse kidney events 1, 2, 3
Albumin may be considered in select indications, but its use should be cautious to avoid volume overload, as excessive use can precipitate pulmonary edema and respiratory failure 1, 3

The European Society of Intensive Care Medicine recommends targeting a MAP of 65 mm Hg, but individualizing based on frequent assessment of end-organ perfusion, rather than rigid adherence to a single number, in patients with chronic liver disease and vasodilatory shock 1, 4
Central venous access should be established for central venous oxygen saturation monitoring and reliable vasopressor delivery once initial stabilization is achieved 1, 4